99 related articles for article (PubMed ID: 16011043)
1. Possible involvement of prolactin in endocrine-resistant metastatic prostate cancer.
Lissoni P; Bignami A; Frontini L; Manganini V; Dapretto E; Gardani GS; Viganò P; Strada G
Int J Biol Markers; 2005; 20(2):123-5. PubMed ID: 16011043
[TBL] [Abstract][Full Text] [Related]
2. Possible involvement of prolactin in endocrine-resistant metastatic prostate cancer.
Lissoni P; Bignami A; Frontini L; Manganini V; Dapretto E; Gardani GS; Vigan P; Strada G
Int J Biol Markers; 2005; 20(2):123-125. PubMed ID: 28207138
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of tamoxifen in hormone-resistant metastatic prostate cancer: possible relation with prolactin secretion.
Lissoni P; Vigano P; Vaghi M; Frontini L; Giuberti C; Manganini V; Casu M; Brivio F; Niespolo R; Strada G
Anticancer Res; 2005; 25(5):3597-9. PubMed ID: 16101186
[TBL] [Abstract][Full Text] [Related]
4. Chromogranin A blood concentrations in relation to those of prolactin in hormone-refractory metastatic prostate cancer: possible existence of two independent mechanisms responsible for endocrine resistance.
Lissoni P; Viganò P; Podraska A; Brivio R; Colciago M; Casu M; Manganini V; Giuberti C; Strada G; Gardani G
Int J Biol Markers; 2006; 21(1):58-9. PubMed ID: 16711515
[No Abstract] [Full Text] [Related]
5. Paradoxical stimulation of prolactin secretion by L-dopa in metastatic prostate cancer and its possible role in prostate-cancer-related hyperprolactinemia.
Lissoni P; Mandalà M; Rovelli F; Casu M; Rocco F; Tancini G; Scardino E
Eur Urol; 2000 May; 37(5):569-72. PubMed ID: 10765095
[TBL] [Abstract][Full Text] [Related]
6. Effect of bicalutamide therapy on prolactin response to L-dopa in metastatic prostate cancer patients.
Lissoni P; Malugani F; Casu M; Bukovec R; Egardi R; Bordin V; Fumagalli E; Mengo S; Gardani G
Neuro Endocrinol Lett; 2002 Feb; 23(1):61-3. PubMed ID: 11880864
[TBL] [Abstract][Full Text] [Related]
7. Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease.
Berruti A; Mosca A; Tucci M; Terrone C; Torta M; Tarabuzzi R; Russo L; Cracco C; Bollito E; Scarpa RM; Angeli A; Dogliotti L
Endocr Relat Cancer; 2005 Mar; 12(1):109-17. PubMed ID: 15788643
[TBL] [Abstract][Full Text] [Related]
8. Investigative clinical study on prostate cancer part VII: prolactin and the pituitary-testis-prostate axis at the time of initial diagnosis and subsequent cluster selection of the patient population.
Porcaro AB; Ghimenton C; Petrozziello A; Migliorini F; Romano M; Sava T; Caruso B; Cocco C; Antoniolli SZ; Lacola V; Rubilotta E; Monaco C; Comunale L
Anticancer Res; 2011 Nov; 31(11):3913-20. PubMed ID: 22110219
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of monochemotherapy with docetaxel (taxotere) in relation to prolactin secretion in heavily pretreated metastatic breast cancer.
Lissoni P; Vaghi M; Ardizzoia A; Fumagalli E; Tancini G; Gardani G; Conti A; Maestroni GJ
Neuro Endocrinol Lett; 2001; 22(1):27-9. PubMed ID: 11335876
[TBL] [Abstract][Full Text] [Related]
10. Biological response modifiers of cancer-related neuroendocrine disorders: efficacy of the long-term dopaminergic agonist cabergoline in the treatment of breast cancer-induced hyperprolactinemia.
Lissoni P; Vaghi M; Pescia S; Rovelli F; Ardizzola A; Valtulina F; Malugani F; Gardani G; Tancini G
J Biol Regul Homeost Agents; 2004; 18(3-4):291-4. PubMed ID: 15786695
[TBL] [Abstract][Full Text] [Related]
11. Investigative clinical study on prostate cancer part VIII: prolactin hormone and the pituitary-testicular-prostate axis at the time of initial diagnosis and subsequent cluster selection of the patient population after radical prostatectomy.
Porcaro AB; Ghimenton C; Petrozziello A; Migliorini F; Romano M; Sava T; Caruso B; Cocco C; Antoniolli SZ; Lacola V; Rubilotta E; Monaco C; Comunale L
Anticancer Res; 2012 Apr; 32(4):1499-506. PubMed ID: 22493393
[TBL] [Abstract][Full Text] [Related]
12. HER2 expression in breast cancer: correlation with endocrine function and psychological status in operable and metastatic breast cancer.
Lissoni P; Messina G; Rovelli F; Brivio F; Fumagalli L; Villa S; Bartolacelli E
In Vivo; 2009; 23(6):987-9. PubMed ID: 20023245
[TBL] [Abstract][Full Text] [Related]
13. A clinical study of taxotere versus taxotere plus the antiprolactinemic agent bromocriptine in metastatic breast cancer pretreated with anthracyclines.
Lissoni P; Bucovec R; Malugani F; Ardizzoia A; Villa S; Gardani GS; Vaghi M; Tancini G
Anticancer Res; 2002; 22(2B):1131-4. PubMed ID: 12168912
[TBL] [Abstract][Full Text] [Related]
14. Endocrinological study of the dopaminergic regulation of prolactin release in metastatic breast cancer.
Mandalà M; Lissoni P; Ardizzoia A; Barni S; Rovelli F; Confalonieri G; Malugani F; Moro C; Fumagalli G; Giani L; Tancini G
Tumori; 1999; 85(6):494-7. PubMed ID: 10774572
[TBL] [Abstract][Full Text] [Related]
15. Changes in chromogranin a serum levels during endocrine therapy in metastatic prostate cancer patients.
Sasaki T; Komiya A; Suzuki H; Shimbo M; Ueda T; Akakura K; Ichikawa T
Eur Urol; 2005 Aug; 48(2):224-9; discussion 229-30. PubMed ID: 16005374
[TBL] [Abstract][Full Text] [Related]
16. [Plasma chromogranin-A (CgA)--a potential marker for diagnosis, monitoring and management of prostate cancer patients].
Leibovitch I; Pinthus Y; Sella BA; Ramon J
Harefuah; 2006 Jan; 145(1):25-9, 78. PubMed ID: 16450720
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of the efficacy of weekly low-dose taxotere by the long acting anti-prolactinemic drug cabergoline in pretreated metastatic breast cancer.
Frontini L; Lissoni P; Vaghi M; Perego MS; Pescia S; Ardizzoia A; Gardani G
Anticancer Res; 2004; 24(6):4223-6. PubMed ID: 15736476
[TBL] [Abstract][Full Text] [Related]
18. Variation in chromogranin A serum levels during intermittent versus continuous androgen deprivation therapy for prostate adenocarcinoma.
Sciarra A; Monti S; Gentile V; Mariotti G; Cardi A; Voria G; Lucera R; Di Silverio F
Prostate; 2003 May; 55(3):168-79. PubMed ID: 12692782
[TBL] [Abstract][Full Text] [Related]
19. Effect of nonsteroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma.
Sciarra A; Di Silverio F
Urology; 2004 Mar; 63(3):523-7. PubMed ID: 15028450
[TBL] [Abstract][Full Text] [Related]
20. Elevated serum chromogranin A precedes prostate-specific antigen elevation and predicts failure of androgen deprivation therapy in patients with advanced prostate cancer.
Chuang CK; Wu TL; Tsao KC; Liao SK
J Formos Med Assoc; 2003 Jul; 102(7):480-5. PubMed ID: 14517586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]